Document is current

Article History

Received: 3 October 2022

Accepted: 23 June 2023

First Online: 29 June 2023

Declarations

:

: This study involved human participants and was approved by the Ethics Committee of Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Lisboa (UIC/1441, 09/09/2021). Informed consent for participation was not required for this study in accordance with national law [CitationRef removed].

: According to the National Law, it is foreseen that patient data are registered under a National database, mandatory for all hospitals treating cancer in Portugal, and consents publication of data in an anonymized and aggregated compiled format [CitationRef removed].

: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. DMB declares having received honoraria and advisory board fees from Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Janssen, Pfizer, Angelini, and AstraZeneca; meeting/travel grants from Novartis, Merck Sharp & Dohme, LEO Farmacêuticos, Ipsen, Janssen, Roche, Laboratórios Vitória, and Gilead Sciences; institutional grants from Novartis and F. Hoffmann-La Roche Ltd, all of which outside the remit of the current project. AF declares having received honoraria and advisory board fees from Daiichi Sankyo, Gilead, Merck Sharp & Dohme, Novartis, Roche; and meeting/travel grants from Roche. FAC, FCB, AR, CB, CR, AL, ACM, MC, CF, AM and ClB declare no competing interests.